Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.5B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Tesla
TSLA
|
+$951M |
| 4 |
Johnson & Johnson
JNJ
|
+$750M |
| 5 |
UnitedHealth
UNH
|
+$703M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$913M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$257M |
| 3 |
NVIDIA
NVDA
|
+$225M |
| 4 |
Vertiv
VRT
|
+$164M |
| 5 |
JPMorgan Chase
JPM
|
+$161M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.48% |
| 2 | Healthcare | 7.36% |
| 3 | Financials | 6.5% |
| 4 | Consumer Discretionary | 5.35% |
| 5 | Industrials | 3.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Albertsons Companies
ACI
$5.83B
| $14.6M | 0.01% |
706,150
+530,564
| +302% | +$11.7M |
|
1027
Rivian
RIVN
$23.2B
| $14.6M | 0.01% |
791,795
+563,916
| +247% | +$16.6M |
|
1028
PUT
Accenture
ACN
$108B
| $14.6M | 0.01% |
54,600
+39,600
| +264% | +$11M |
|
1029
Vanguard FTSE Emerging Markets ETF
VWO
$126B
| $14.6M | 0.01% |
373,704
-1,397,864
| -79% | -$53.3M |
|
1030
Charles River Laboratories
CRL
$12.8B
| $14.6M | 0.01% |
66,776
-5,004
| -7% | -$1.09M |
|
|
NVO
1031
CALL
Novo Nordisk
NVO
$209B
| $14.5M | 0.01% |
+215,000
| New | +$12.6M |
|
1032
Plains GP Holdings
PAGP
$4.9B
| $14.5M | 0.01% |
1,168,700
-71,783
| -6% | -$895K |
|
|
JJG
1033
DELISTED
iPath Series B Bloomberg Grains Subindex Total ReturnSM ETN
JJG
| $14.4M | 0.01% |
186,000
| – | – |
|
|
EXAS
1034
DELISTED
Exact Sciences
EXAS
| $14.4M | 0.01% |
290,950
-9,787
| -3% | -$400K |
|
|
CERE
1035
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $14.4M | 0.01% |
456,615
+358,880
| +367% | +$10.1M |
|
1036
PUT
Akamai
AKAM
$15.9B
| $14.4M | 0.01% |
+170,400
| New | +$14.8M |
|
1037
CALL
Sunrun
RUN
$2.46B
| $14.3M | 0.01% |
+597,100
| New | +$15.9M |
|
1038
Teladoc Health
TDOC
$1.3B
| $14.3M | 0.01% |
606,095
-198,885
| -25% | -$5.36M |
|
1039
Rexford Industrial Realty
REXR
$8.19B
| $14.3M | 0.01% |
262,246
-178,323
| -40% | -$9.61M |
|
|
GAP
1040
The Gap Inc
GAP
$7.37B
| $14.3M | 0.01% |
1,268,847
+56,468
| +5% | +$676K |
|
1041
Insulet
PODD
$9.79B
| $14.3M | 0.01% |
48,616
+10,934
| +29% | +$3.02M |
|
|
MRO
1042
PUT
DELISTED
Marathon Oil Corporation
MRO
| $14.3M | 0.01% |
+528,300
| New | +$15.3M |
|
1043
Entegris
ENTG
$23.2B
| $14.3M | 0.01% |
217,856
-113,288
| -34% | -$8.34M |
|
1044
PUT
Petrobras
PBR
$116B
| $14.3M | 0.01% |
+1,341,400
| New | +$16.2M |
|
1045
Match Group
MTCH
$8.55B
| $14.3M | 0.01% |
344,317
+23,587
| +7% | +$1.07M |
|
1046
Equity Lifestyle Properties
ELS
$12.6B
| $14.3M | 0.01% |
220,800
+30,588
| +16% | +$1.94M |
|
1047
Vale
VALE
$62.6B
| $14.2M | 0.01% |
838,403
-888,215
| -51% | -$13.4M |
|
1048
iShares MSCI Canada ETF
EWC
$6.46B
| $14.2M | 0.01% |
434,653
+409,363
| +1,619% | +$13.6M |
|
1049
CALL
BILL Holdings
BILL
$4.78B
| $14.2M | 0.01% |
130,000
+20,000
| +18% | +$2.4M |
|
1050
LPL Financial
LPLA
$28.6B
| $14.1M | 0.01% |
65,290
-12,318
| -16% | -$2.88M |
|
Similar funds
Barclays's Q4 2022 Portfolio in Review
As of Q4 2022, Barclays held 5,646 positions worth $223B, up 144% from $91.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $128B of net new capital in Q4 2022, opening 797 new positions and adding to 2,634 existing holdings. Its largest new stake was Seadrill: 1,546,558 shares worth $50.5M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $257M trimmed.
- Barclays's largest Q4 2022 buy was Seadrill: 1,546,558 shares worth $50.5M.
- Barclays added most to Microsoft in Q4 2022, an estimated $2.5B increase.
- Barclays's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $257M.
- Barclays fully exited Citrix Systems Inc in Q4 2022, selling an estimated $913M.
- Barclays's ten largest holdings make up 41% of its $223B portfolio in Q4 2022.
- Barclays opened 797 new positions and closed 385 in Q4 2022.
- Barclays's portfolio value rose 144% quarter-over-quarter to $223B.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.